Ractigen Therapeutics
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3b 4th Floor Bldg.1 Biobay 99, Suzhou, J...Phone Number
+8651381996959Website
www.ractigen.comRevenue
$16.9 MillionIndustry
About Ractigen Therapeutics
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as small activating RNAs (saRNA), to specifically up-regulate targeted endogenous genes for boosting therapeutic protein production. Supporting its core platform, Ractigen Therapeutics has created the SCAD delivery system allowing enhanced biodistribution throughout extrahepatic tissue and built a rich pipeline of first-in-class candidate medicines for patients with unmet genetic disorders.Explore more
SIC Code 28,283NAICS Code 32,325Show moreRactigen Therapeutics Org Chart
Ractigen Therapeutics Tech Stack
A closer look at the technologies used by Ractigen Therapeutics
See more technologies
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ractigen Therapeutics
Sign Up For FreeTo access detailed company insights
Ractigen Therapeutics was founded in 2017 by pioneers of the RNAa technology including Dr. Long-Cheng Li and his longstanding colleagues Dr. Robert Place and Dr. Moorim Kang. Ractigen is a late-stage preclinical pharmaceutical company devoted to creating groundbreaking therapies based on the RNAa platform. RNAa utilizes short duplex RNAs, known as... Read More

